An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

A phase 3 trial found that PSMA PET-CT after equivocal MRI halves the prostate biopsy rate in men at high clinical risk for prostate cancer. In men with high clinical risk and equivocal prostate ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation. Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The Journal of ...

MILAN — When added to prostate biopsy, gallium-68 prostate-specific membrane antigen (PSMA)-PET/CT improves detection of clinically significant prostate tumors and helps guide treatment planning, new ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and ...